Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
Date:7/20/2009

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Greifensee, Switzerland (PRWEB) October 01, 2014 ... influence the quality of the final product. However, ... most regulated, regulatory frameworks such as Good Manufacturing ... is the responsibility of the manufacturer to interpret ... ensure consistent weighing performance quality. METTLER TOLEDO experts ...
(Date:10/1/2014)... Today the National Institutes of ... for the Brain Research through Advancing Innovative Neurotechnologies ... and revolutionize new methods of understanding the complexities ... This first round of grants totaling $46 million ... to more than 100 investigators in 15 states ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2
... Expands Decision Resources, Inc.,s Portfolio to Include Global ... Physician and Consumer Digital Market Research, ... Inc., one of the world,s leading research and advisory ... it,acquired Manhattan Research, a leading provider of access to ...
... AVIV, Israel, June 17 BSP Ltd.,( http://www.bsp.co.il/pressall.asp ... for non-invasive diagnosis and monitoring of Ischemic Heart,Disease, ... a private,funding round, that included existing shareholders in ... developed the HyperQ(TM), a cutting-edge technology that offers,highly ...
... and fast PCR amplification ... in a fully portable ... a leading,developer of state-of-the-art PCR devices and Cell-based assay systems,today ... San,Diego Convention Center that it has successfully completed development of,Palm ...
Cached Biology Technology:Decision Resources, Inc. Acquires Manhattan Research 2Decision Resources, Inc. Acquires Manhattan Research 3BSP Raises $2.6 Million Dollars From Private Investors 2Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device 2
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2
... As the 2010 United Nations International Year of ... (MBG) and the Royal Botanic Gardens, Kew (RBG Kew) ... international resource is a working list of all land ... diversity and effective conservation of plants. The completion of ...
... In a recent issue of HortTechnology , Purdue ... on a study of the effects of a technique called ... are commonly applied as sprays or media drenches, bulb crops ... The experiments were designed to determine if dipping Easter lily ...
... Dec. 29, 2010 Patients with diabetes, kidney disease and ... have a higher risk of cardiovascular disease or death, researchers ... results suggest that testing such patients, responsiveness to the drug ... their risk, said Dr. Robert Toto, professor of internal medicine ...
Cached Biology News:Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 2Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 3Bulb dipping controls Easter lily growth 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 3
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: